ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

Despite initial benefits in treating HER2-positive breast cancer patients with lapatinib, resistance is prevalent. Here the authors show that lapatinib resistance can be ascribed to mTOR-mediated re-activation of ERRα and to the consequent induction of a metabolic adaptation.

Guardado en:
Detalles Bibliográficos
Autores principales: Geneviève Deblois, Harvey W. Smith, Ingrid S. Tam, Simon-Pierre Gravel, Maxime Caron, Paul Savage, David P. Labbé, Louis R. Bégin, Michel L. Tremblay, Morag Park, Guillaume Bourque, Julie St-Pierre, William J. Muller, Vincent Giguère
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2016
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/a807b71593d5451987bf6593688f61a3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/a807b71593d5451987bf6593688f61a3

Ejemplares similares